Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabi-HB SC in post-liver transplant Hepatitis B
NCT00800787Phase 3Withdrawn
- Sponsor
- Biotest AG
- Start
- Apr 2010
- Primary completion
- Aug 2010
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 3, open-label, single-arm trial of hepatitis B immune globulin in hepatitis B (HBV), sponsored by Biotest AG. Primary endpoint: Anti-HBs levels > 150 IU/ML at 14 weeks. Planned start Apr 2010; status: withdrawn.
02
Drugs
hepatitis B immune globulin
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00800787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800787.